President and CEO, Qpex Biopharma
Dr. Dudley has over 30 years of experience in antiinfective drug research and development, with experience in the discovery, preclinical and clinical stages in both academia and industry. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor combination product from a new chemical class (vaborbactam) discovered in the company laboratories. The combination product Vabomere™ advanced from discovery to FDA approval in 2017 in < 8 years. He has lead the negotiation for multiple contracts from public-private partnerships (e.g., BARDA of the US Government) for ~ $200 million funding to advance antimicrobial agents in development in the US and Europe. He recently co-founded Qpex Pharmaceuticals which raised $33M in Series A financing and acquired the preclinical infectious disease programs from The Medicines Company.
Prior to his current position, he was held positions of increasing responsibilities at small biotech companies Microcide Pharmaceuticals, Diversa Corporation, and Mpex Pharmaceuticals. Following the acquisition of Mpex, he co-founded Rempex Pharmaceuticals as the CSO. When Rempex was acquired by the Medicines Company (MDCO), he remained as the co-leader of the Infectious Disease Business Unit of MDCO. Prior to his career in pharmaceutical industry, he held full-time academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and Adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted research in infectious disease, including important clinical studies (Phase I-IV) and pioneering work describing PK-PD approaches for study of several classes of antibacterial, antifungal, and antiviral agents.
Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, and at international meetings on infectious diseases. He has served as an Editor for the journal Antimicrobial Agents and Chemotherapy and numerous other editorial and advisory boards. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (Pharm.D.) from the University of California San Francisco (UCSF), completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.